JAMA Internal Medicine
@JAMAInternalMed
Followers
108K
Following
346
Media
4K
Statuses
30K
JAMA Internal Medicine is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.
Chicago, IL
Joined July 2009
✍️ This Teachable Moment discusses a case of hypotension caused by severe adrenal insufficiency in a man in his 70s.
jamanetwork.com
This Teachable Moment discusses a case of hypotension caused by severe adrenal insufficiency in a man in his 70s.
0
0
1
Among pregnant women, oral corticosteroid use was not linked to higher rates of gestational #diabetes, except for a slight increase with exposure between weeks 4–6.
jamanetwork.com
This cohort study assesses the association between oral corticosteroid use during pregnancy and the risk of gestational diabetes among women in Korea.
0
2
5
Today, @WHO published a guideline in @JAMA_current on the use and indications of #GLP-1 therapies for the management of #obesity in adults. Explore the new guideline: https://t.co/zsACvoKr2K Join WHO for a public, live-streamed webinar at 10 AM ET: https://t.co/ylW50vPN2D
0
3
13
@JAMA_current @WHO Today at 10 AM EST, JAMA Editor in Chief @KBibbinsDomingo, PhD, MD, MAS, will moderate a public, live-streamed webinar hosted by WHO about the new guideline. Register: https://t.co/qc9xWmVp3f
who.int
Obesity affects more than one billion people worldwide and remains a leading cause of chronic disease and premature death. To address this growing global challenge, the World Health Organization...
0
0
1
@JAMA_current @WHO The second recommendation advises pairing GLP-1 therapy with structured behavioral interventions, including dietary and physical activity goals, counseling, and regular monitoring, based on low-certainty evidence from recent research.
1
0
1
Elon Musk: "think Google is going to be pretty valuable in the future. They have laid the groundwork for an immense amount of value creation from an AI standpoint. Nvidia is obvious at this point.”
1
0
17
@JAMA_current @WHO Recommendation #1: Long-term GLP-1 therapy may be considered for weight management in adults living with obesity, based on mid-certainty evidence from ongoing trials.
1
0
0
@JAMA_current Obesity affects more than 1 billion people worldwide and is recognized by @WHO as a chronic, relapsing disease linked to substantial morbidity, mortality, and economic burden. WHO has two conditional recommendations.
1
0
0
Today, WHO published a guideline in @JAMA_current on the use and indications of #GLP1 therapies, including GLP-1 receptor agonists and GLP-1/GIP dual agonists, for the global treatment of #obesity in adults. https://t.co/D3hprkBsVG 🧵
1
0
2
We taste over 5,000 wines a year. Only 4% make the cut. You almost picked one of them. Not some mass-market label. Not a bottle you’ll find on grocery shelves. This is the kind of wine you remember. And you were one click away. Join the 4%.
9
81
392
Are antiviral medications beneficial for patients with mild to moderate influenza? A study published in JAMA Internal Medicine found that antivirals make little difference in the outpatient setting, although baloxavir may be superior to standard care. 🔗 https://t.co/OX9ttemo2z
0
0
2
On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new @WHO guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: https://t.co/4QT8tnDB5J
0
0
1
💬 Viewpoint: Inhaler price caps announced by manufacturers contain major gaps, excluding many Medicare and Medicaid beneficiaries due to federal regulations. https://t.co/BTKsyL5xPf
0
1
5
Teachable Moment: Sexual health issues are often unaddressed in #cancer care, affecting quality of life and treatment decisions for patients, especially sexual and gender minorities. https://t.co/JNqaWmZ9QC
0
0
0
On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new WHO guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: https://t.co/Xr0KaNxN82
1
1
8
Most speakers who attended FDA Advisory Committee meetings about new drugs or indications supported approval, including nearly all who identified as patients and family members. https://t.co/ouKH2UHPIq
1
1
7
In the SURMOUNT-4 trial, 82.5% of adults with obesity regained ≥25% of initial weight lost within one year of tirzepatide withdrawal; most showed reversal of cardiometabolic improvements. https://t.co/eX8xLaKaS6
7
53
127
Continuous glucose monitoring (CGM) enables real-time assessment of glucose trends in individuals with type 2 #diabetes, complementing or replacing fingerstick and HbA1c monitoring. 💡 This @JAMA_current Insights discusses CGM use for type 2 diabetes. https://t.co/d7k49WafUQ
1
6
22
From @JAMA_current: #GLP-1 receptor agonist exposure with discontinuation before or during early #pregnancy was associated with greater gestational weight gain and increased risk of preterm delivery, gestational #diabetes, and hypertensive disorders. https://t.co/Kb6uRpeGc0
0
1
13
From @JAMA_current: Postpartum prescription of #GLP-1RAs in Denmark increased between 2018 and 2024, with #semaglutide accounting for most prescriptions since 2023. Most users had #overweight or #obesity, and only 23% had a #diabetes diagnosis. https://t.co/yUjfy6mGKc
0
0
3
Among US veterans aged 60 and over, #RSV vaccine effectiveness against infection declined from 82.5% at 1 month post-vaccination to 59.4% at 18 months. https://t.co/qAOYhyAx0b
0
0
2
💬 Editorial: #RSV vaccine effectiveness in adults aged 60 and over is high at 1 month (82.5%), then declines over 18 months (59.4%), raising considerations for booster dosing in future guidance. https://t.co/IFFf6FzJ4D
0
0
2